DBV Technologies (NASDAQ:DBVT) Major Shareholder Bpifrance Epic Sells 2,076,990 Shares of Stock

DBV Technologies S.A. (NASDAQ:DBVT) major shareholder Bpifrance Epic sold 2,076,990 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $4.85, for a total value of $10,073,401.50. Following the completion of the transaction, the insider directly owned 8,595,472 shares of the company’s stock, valued at approximately $41,688,039.20. The trade was a 19.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Bpifrance Epic also recently made the following trade(s):

• On Thursday, December 18th, Bpifrance Epic sold 1,292,103 shares of DBV Technologies stock. The shares were sold at an average price of $4.19, for a total value of $5,413,911.57.

DBV Technologies Trading Up 5.8%

NASDAQ:DBVT opened at $22.76 on Friday. The stock’s 50-day moving average is $15.38 and its 200-day moving average is $11.83. DBV Technologies S.A. has a 1-year low of $2.92 and a 1-year high of $26.18. The stock has a market cap of $914.04 million, a P/E ratio of -4.40 and a beta of -1.10.

Key Headlines Impacting DBV Technologies

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: Phase‑III win in peanut allergy improves commercial/clinical outlook — a Bioworld report says DBV’s VIT® program delivered a positive Phase III result, a material de‑risking event for a lead program that can drive future revenue and re‑rating. Vitesse finesse pays off: DBV wins in peanut allergy phase III
• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts, signaling stronger long‑term profitability expectations (FY2027–FY2029 upgrades). That upward revision likely helped investor sentiment and price momentum. HC Wainwright Expects Stronger Earnings for DBV Technologies
• Positive Sentiment: Additional bullish analyst notes and coverage changes — the stock was reported to hit a new 1‑year high after analyst upgrades, and coverage consensus sits around a “Moderate Buy,” with at least one firm (Citizens JMP) forecasting strong price appreciation. Those actions typically boost retail/institutional interest. DBV Technologies (NASDAQ:DBVT) Hits New 1-Year High Following Analyst Upgrade
• Neutral Sentiment: Market consensus EPS remains deeply negative for the current year (consensus ~($7.05) EPS), so while upgrades are meaningful, the company is still transitioning from loss‑making to profitable — investors should watch upcoming milestones and cash runway closely.
• Negative Sentiment: Major shareholder Bpifrance Epic sold large blocks of stock on Dec 17–18 (combined ~3.37M shares sold across two days, materially reducing its stake). Large insider/major‑holder selling can pressure the stock and signal liquidity‑driven exits even when fundamentals improve. SEC filing: Bpifrance Epic Insider Sales SEC Filing
• Negative Sentiment: Lifesci Capital trimmed its FY2026 EPS estimate (worse near‑term profitability view), a reminder that boutique analysts still see near‑term execution and cash burn risk — this can cap upside until revenue/profitability is proven.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in DBVT. Vivo Capital LLC bought a new stake in shares of DBV Technologies during the 2nd quarter valued at about $9,659,000. Adage Capital Partners GP L.L.C. bought a new position in shares of DBV Technologies during the 2nd quarter worth approximately $9,659,000. MPM Bioimpact LLC acquired a new stake in shares of DBV Technologies during the 2nd quarter worth approximately $9,649,000. Octagon Capital Advisors LP bought a new stake in shares of DBV Technologies in the 2nd quarter valued at $9,315,000. Finally, Millennium Management LLC increased its stake in shares of DBV Technologies by 26.1% in the 3rd quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock valued at $3,379,000 after acquiring an additional 69,849 shares in the last quarter. 71.74% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on DBVT. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research note on Wednesday. Cantor Fitzgerald set a $48.00 target price on DBV Technologies in a research report on Wednesday. Zacks Research raised DBV Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Weiss Ratings restated a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, December 8th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $51.00 price objective (up from $35.00) on shares of DBV Technologies in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, DBV Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.38.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.